-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation 2014 4:9, 847-865.
Corrigendum: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Konstantinos Z Vardakas & Matthew E Falagas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stephane Paul, Emilie Del Tedesco
Review: Clinical Trail Outcomes: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation